サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1786995

非ホジキンリンパ腫治療薬市場、規模、シェア、動向、産業分析レポート：細胞タイプ別、治療タイプ別、投与経路別、地域別-2025年～2034年市場予測

Non-Hodgkin Lymphoma Therapeutics Market Size, Share, Trends, & Industry Analysis Report By Cell Type (B-cell lymphomas, T-cell lymphoma),By Therapy Type, By Route of Administration, and By Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 128 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
非ホジキンリンパ腫治療薬市場、規模、シェア、動向、産業分析レポート：細胞タイプ別、治療タイプ別、投与経路別、地域別-2025年～2034年市場予測
出版日: 2025年07月01日
発行: Polaris Market Research
ページ情報: 英文 128 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、非ホジキンリンパ腫治療薬市場規模は2034年までに189億米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

非ホジキンリンパ腫治療薬は、有効性、安全性、患者の生存期間の延長に焦点を当て、多様なリンパ系がんのサブタイプに対処するように設計された幅広い標的治療を指します。これらの治療薬は、正確性、一貫性、良好な治療効果を保証するために、厳格な臨床基準の下で開発されています。

市場の成長には、世界のがん罹患率の増加と、安全性プロファイルを改善した効果的な標的治療薬に対する緊急のニーズが拍車をかけています。がん免疫療法、モノクローナル抗体、CAR-T細胞治療の進歩は、再発難治性非ホジキンリンパ腫の臨床転帰を向上させています。ヘルスケア投資の増加と規制当局の支援策により、世界の主要治療センターにおける次世代リンパ腫治療薬の開発と利用がさらに加速しています。

非ホジキンリンパ腫治療薬市場レポートハイライト

細胞タイプ別では、B細胞リンパ腫セグメントが2024年に市場で最大シェアを占めました。これは、B細胞リンパ腫の有病率が高く、寛解率と長期生存率を改善する標的治療オプションの利用可能性が高まっているためです。

治療法の種類別にみると、標的療法は、健康な組織へのダメージを最小限に抑えつつ、がん細胞を正確に攻撃することから、急成長が見込まれています。

投与経路別では、投与量と有効性をコントロールしながら生物製剤や化学療法を投与するために病院や腫瘍センターで広く使用されている静脈内投与が2024年の市場シェアを独占しました。

北米は2024年に世界の非ホジキンリンパ腫治療薬市場で最大のシェアを占めたが、これは旺盛なヘルスケア支出とリンパ腫治療薬開発に従事する主要バイオ製薬企業の存在に後押しされたものです。

アジア太平洋は、がん負担の増加と先進治療へのアクセスの増加により、予測期間中に市場シェアが大幅なCAGRで成長すると予想されます。

世界の主要市場企業には、AbbVie Inc.、AstraZeneca PLC、Baxter International Inc.、Bayer AG、Bristol Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、Gilead Sciences, Inc.、GlaxoSmithKline PLC、Janssen Biotech, Inc.、Teva Pharmaceutical Industries Ltd.、Verismo Therapeutics, Inc.などがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の非ホジキンリンパ腫治療薬市場の洞察

  • 市場スナップショット
  • 非ホジキンリンパ腫治療薬市場力学
    • 促進要因と機会
      • 政府のヘルスケア費支出の増加
      • 世界中でNHLの症例が増加
    • 抑制要因と課題
      • 高額な治療費
  • PESTEL分析
  • 非ホジキンリンパ腫治療薬市場の動向
  • バリューチェーン分析

第5章 世界の非ホジキンリンパ腫治療薬市場：細胞タイプ別

  • 主な調査結果
  • イントロダクション
  • B細胞リンパ腫
  • T細胞リンパ腫

第6章 世界の非ホジキンリンパ腫治療薬市場：治療タイプ別

  • 主な調査結果
  • イントロダクション
  • 化学療法
  • 標的療法
  • 放射線治療
  • その他の治療法

第7章 世界の非ホジキンリンパ腫治療薬市場：投与経路別

  • 主な調査結果
  • イントロダクション
  • 経口
  • 静脈内
  • 皮下

第8章 世界の非ホジキンリンパ腫治療薬市場：地域別

  • 主な調査結果
  • イントロダクション
    • 非ホジキンリンパ腫治療薬市場分析：地域、2020年～2034年
  • 北米
    • 北米：細胞タイプ別、2020年～2034年
    • 北米：治療タイプ別、2020年～2034年
    • 北米：投与経路別、2020年～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：細胞タイプ別、2020年～2034年
    • 欧州：治療タイプ別、2020年～2034年
    • 欧州：投与経路別、2020年～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋：細胞タイプ別、2020年～2034年
    • アジア太平洋：治療タイプ別、2020年～2034年
    • アジア太平洋：投与経路別、2020年～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ
    • 中東・アフリカ：細胞タイプ別、2020年～2034年
    • 中東・アフリカ：治療タイプ別、2020年～2034年
    • 中東・アフリカ：投与経路別、2020年～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：細胞タイプ別、2020年～2034年
    • ラテンアメリカ：治療タイプ別、2020-2034年
    • ラテンアメリカ：投与経路別、2020年～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • AbbVie Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann La-Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Janssen Biotech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Verismo Therapeutics, Inc.
図表

List of Tables:

  • Table 1 Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 2 Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 3 Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 4 North America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 5 North America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 6 North America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 7 US: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 8 US: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 9 US: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 10 Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 11 Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 12 Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 13 Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 14 Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 15 Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 16 UK: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 17 UK: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 18 UK: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 19 France: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 20 France: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 21 France: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 22 Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 23 Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 24 Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 25 Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 26 Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 27 Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 28 Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 29 Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 30 Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 31 Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 32 Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 33 Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 34 Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 35 Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 36 Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 37 Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 38 Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 39 Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 40 Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 41 Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 42 Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 43 China: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 44 China: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 45 China: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 46 India: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 47 India: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 48 India: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 49 Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 50 Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 51 Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 52 Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 53 Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 54 Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 55 Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 56 Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 57 Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 58 South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 59 South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 60 South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 61 Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 62 Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 63 Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 64 Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 65 Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 66 Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 67 Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 68 Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 69 Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 70 Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 71 Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 72 Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 73 UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 74 UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 75 UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 76 Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 77 Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 78 Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 79 South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 80 South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 81 South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 82 Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 83 Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 84 Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 85 Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 86 Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 87 Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 88 Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 89 Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 90 Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 91 Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 92 Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 93 Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 94 Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 95 Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 96 Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • Table 97 Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • Table 98 Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • Table 99 Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Non-Hodgkin Lymphoma Therapeutics Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Cell Type
  • Figure 7. Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Therapy Type
  • Figure 9. Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Route of Administration
  • Figure 11. Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2024 & 2034 (USD Billion)
目次
Product Code: PM6004

The Non-Hodgkin lymphoma therapeutics market size is expected to reach USD 18.90 Billion by 2034, according to a new study by Polaris Market Research. The report "Non-Hodgkin Lymphoma Therapeutics Market Share, Size, Trends, Industry Analysis Report: By Cell Type (B-cell lymphomas, T-cell lymphoma), By Therapy Type, By Route of Administration, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Non-Hodgkin lymphoma therapeutics refer to a broad spectrum of targeted treatments designed to address diverse lymphatic cancer subtypes, focusing on efficacy, safety, and prolonged patient survival. These therapies are developed under stringent clinical standards to ensure precision, consistency, and favorable treatment response.

The market growth is fueled by increasing global cancer incidence and the urgent need for effective targeted therapies with improved safety profiles. Advancements in cancer immunotherapy, monoclonal antibodies, and CAR-T cell treatments are enhancing clinical outcomes for relapsed and refractory NHL cases. Rising healthcare investments and supportive regulatory pathways are further accelerating the development and accessibility of next-generation lymphoma therapeutics across major treatment centers worldwide.

Non-Hodgkin Lymphoma Therapeutics Market Report Highlights

Based on cell type, the B-cell lymphoma segment held largest share of the market in 2024, due to its high prevalence and growing availability of targeted treatment options that improve remission rates and long-term survival outcomes.

Based on therapy type, the targeted therapy segment is expected to witness the fastest growth, due to its precision in attacking cancerous cells while minimizing damage to healthy tissue

Based on route of administration, the intravenous segment held the dominant market share in 2024, driven by the widespread use in hospitals and oncology centers for delivering biologics and chemotherapy with controlled dosage and efficacy.

North America accounted for largest share of the global non-hodgkin lymphoma therapeutics market in 2024, fueled by strong healthcare spending and the presence of leading biopharmaceutical companies engaged in lymphoma drug development.

Asia Pacific is expected to grow with a significant CAGR during the forecast period market share, due to the growing cancer burden and increased access to advanced therapies.

A few global key market players include AbbVie Inc., AstraZeneca PLC, Baxter International Inc., Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Janssen Biotech, Inc., Teva Pharmaceutical Industries Ltd., and Verismo Therapeutics, Inc.

Polaris Market Research has segmented the market report on the basis of cell type, therapy type, route of administration, and region:

By Cell Type Outlook (Revenue, USD Billion, 2020-2034)

B-cell lymphomas

T-cell lymphoma

By Therapy Type Outlook (Revenue, USD Billion, 2020-2034)

Chemotherapy

Targeted therapy

Radiation therapy

Other therapy types

By Route of Administration (Revenue, USD Billion, 2020-2034)

Oral

Intravenous

Subcutaneous

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Non-Hodgkin Lymphoma Therapeutics Market Insights

  • 4.1. Non-Hodgkin Lymphoma Therapeutics Market - Market Snapshot
  • 4.2. Non-Hodgkin Lymphoma Therapeutics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Government Healthcare Spending
      • 4.2.1.2. Rising Cases of NHL Worldwide
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Non-Hodgkin Lymphoma Therapeutics Market Trends
  • 4.6. Value Chain Analysis

5. Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
  • 5.3. B-cell lymphomas
    • 5.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by B-cell lymphomas, by Region, 2020-2034 (USD Billion)
  • 5.4. T-cell lymphomas
    • 5.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by T-cell lymphomas, by Region, 2020-2034 (USD Billion)

6. Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
  • 6.3. Chemotherapy
    • 6.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 6.4. Targeted Therapy
    • 6.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
  • 6.5. Radiation Therapy
    • 6.5.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Radiation Therapy, by Region, 2020-2034 (USD Billion)
  • 6.6. Other Therapy Types
    • 6.6.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Other Therapy Types, by Region, 2020-2034 (USD Billion)

7. Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Oral, by Region, 2020-2034 (USD Billion)
  • 7.4. Intravenous
    • 7.4.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Intravenous, by Region, 2020-2034 (USD Billion)
  • 7.5. Subcutaneous
    • 7.5.1. Global Non-Hodgkin Lymphoma Therapeutics Market, by Subcutaneous, by Region, 2020-2034 (USD Billion)

8. Global Non-Hodgkin Lymphoma Therapeutics Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Non-Hodgkin Lymphoma Therapeutics Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 8.3. Non-Hodgkin Lymphoma Therapeutics Market - North America
    • 8.3.1. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.3.2. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.3.3. North America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.3.4. Non-Hodgkin Lymphoma Therapeutics Market - US
      • 8.3.4.1. US: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.3.4.2. US: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.4.3. US: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.3.5. Non-Hodgkin Lymphoma Therapeutics Market - Canada
      • 8.3.5.1. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.3.5.2. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.3.5.3. Canada: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.4. Non-Hodgkin Lymphoma Therapeutics Market - Europe
    • 8.4.1. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.4.2. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.4.3. Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.4. Non-Hodgkin Lymphoma Therapeutics Market - UK
      • 8.4.4.1. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.4.2. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.4.3. UK: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.5. Non-Hodgkin Lymphoma Therapeutics Market - France
      • 8.4.5.1. France: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.5.2. France: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.5.3. France: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.6. Non-Hodgkin Lymphoma Therapeutics Market - Germany
      • 8.4.6.1. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.6.2. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.6.3. Germany: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.7. Non-Hodgkin Lymphoma Therapeutics Market - Italy
      • 8.4.7.1. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.7.2. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.7.3. Italy: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.8. Non-Hodgkin Lymphoma Therapeutics Market - Spain
      • 8.4.8.1. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.8.2. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.8.3. Spain: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.9. Non-Hodgkin Lymphoma Therapeutics Market - Netherlands
      • 8.4.9.1. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.9.2. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.9.3. Netherlands: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.10. Non-Hodgkin Lymphoma Therapeutics Market - Russia
      • 8.4.10.1. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.10.2. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.10.3. Russia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.4.11. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.4.11.2. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.4.11.3. Rest of Europe: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.5. Non-Hodgkin Lymphoma Therapeutics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.5.2. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.5.3. Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.4. Non-Hodgkin Lymphoma Therapeutics Market - China
      • 8.5.4.1. China: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.4.2. China: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.4.3. China: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.5. Non-Hodgkin Lymphoma Therapeutics Market - India
      • 8.5.5.1. India: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.5.2. India: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.5.3. India: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.6. Non-Hodgkin Lymphoma Therapeutics Market - Malaysia
      • 8.5.6.1. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.6.2. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.6.3. Malaysia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.7. Non-Hodgkin Lymphoma Therapeutics Market - Japan
      • 8.5.7.1. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.7.2. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.7.3. Japan: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.8. Non-Hodgkin Lymphoma Therapeutics Market - Indonesia
      • 8.5.8.1. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.8.2. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.8.3. Indonesia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.9. Non-Hodgkin Lymphoma Therapeutics Market - South Korea
      • 8.5.9.1. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.9.2. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.9.3. South Korea: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.10. Non-Hodgkin Lymphoma Therapeutics Market - Australia
      • 8.5.10.1. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.10.2. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.10.3. Australia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.5.11. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.5.11.2. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.5.11.3. Rest of Asia Pacific: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.6. Non-Hodgkin Lymphoma Therapeutics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.6.2. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.6.3. Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.4. Non-Hodgkin Lymphoma Therapeutics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.4.2. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.5. Non-Hodgkin Lymphoma Therapeutics Market - UAE
      • 8.6.5.1. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.5.2. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.5.3. UAE: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.6. Non-Hodgkin Lymphoma Therapeutics Market - Israel
      • 8.6.6.1. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.6.2. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.6.3. Israel: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.7. Non-Hodgkin Lymphoma Therapeutics Market - South Africa
      • 8.6.7.1. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.7.2. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.7.3. South Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.6.8. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.6.8.2. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.6.8.3. Rest of Middle East & Africa: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
  • 8.7. Non-Hodgkin Lymphoma Therapeutics Market - Latin America
    • 8.7.1. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
    • 8.7.2. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
    • 8.7.3. Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.4. Non-Hodgkin Lymphoma Therapeutics Market - Mexico
      • 8.7.4.1. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.7.4.2. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.4.3. Mexico: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.5. Non-Hodgkin Lymphoma Therapeutics Market - Brazil
      • 8.7.5.1. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.7.5.2. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.5.3. Brazil: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.6. Non-Hodgkin Lymphoma Therapeutics Market - Argentina
      • 8.7.6.1. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.7.6.2. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.6.3. Argentina: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)
    • 8.7.7. Non-Hodgkin Lymphoma Therapeutics Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Cell Type, 2020-2034 (USD Billion)
      • 8.7.7.2. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Therapy Type, 2020-2034 (USD Billion)
      • 8.7.7.3. Rest of Latin America: Non-Hodgkin Lymphoma Therapeutics Market, by Route of Administration, 2020-2034 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Cell Type Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca PLC
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Cell Type Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Baxter International Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Cell Type Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Bayer AG
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Cell Type Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bristol Myers Squibb Company
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Cell Type Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Eli Lilly and Company
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Cell Type Benchmarking
    • 10.6.4. Recent Development
  • 10.7. F. Hoffmann La-Roche Ltd.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Cell Type Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Gilead Sciences, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Cell Type Benchmarking
    • 10.8.4. Recent Development
  • 10.9. GlaxoSmithKline PLC
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Cell Type Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Janssen Biotech, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Cell Type Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Teva Pharmaceutical Industries Ltd.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Cell Type Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Verismo Therapeutics, Inc.
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Cell Type Benchmarking
    • 10.12.4. Recent Development